BioSpace News Archive

Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021.

Inscopix Inc., a leading neurotechnology company in California that empowers breakthroughs in brain science, announced today that Martin Verhoef has joined the company as Chief Commercial Officer. As a key member of Inscopix’s executive leadership team, Mr. Verhoef will lead all commercial operations, spanning strategy, sales, marketing, business development and customer success.

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021.

Second Sight Medical Products, Inc., a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that the Company’s Board of Directors has named Scott Dunbar to replace Matthew Pfeffer as acting Chief Executive Officer.

Presenters include Dr. Amir Azadi of Barrow Neurological Institute, Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University

Aditx Therapeutics, Inc., a biotech innovation company focused on improving the health of the immune system, announced that Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centers. Collection Sites, LLC is owned and operated by Medivolve Inc..

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion

Allergan Aesthetics, an AbbVie company, announces the launch of SkinMedica® Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and décolleté area.

Plexus Research, a division of GP InnoVentures (GPIV), an investment and innovation organization based in Adelaide, Australia, is joining the TriNetX global health research network, to help generate greater access to clinical trials and provide a path to market for groundbreaking medical products.

Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institute of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer’s disease (“AD”) .